This site is intended for U.S. healthcare professionals.
Menu
Close
Menu
Close
MEDICARE CHANGES FOR 2025: Medicare patients will pay no more than $2,000 total for all their Part D medications, including VYNDAMAX, for the full year of 2025.
Nationally, more than 94% of Medicare Part D patients have access to VYNDAMAX after meeting applicable PA criteria.
Medicare patients will have the option to enroll in the Medicare Prescription Payment Plan to spread their drug costs over the course of the year.
Nationally, 90% of commercially insured patients have access to VYNDAMAX after meeting applicable PA criteria
Eligible commercially insured patients may pay as little as $0 per month through the VYNDAMAX Co-Pay Savings Program.
By using this co-pay card, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:
Extra help with Medicare Part D costs is available to qualifying patients. Learn more about the Extra Help Program at Medicare.gov
Connect eligible patients with financial assistance resources
Conduct a benefits verification to determine your patient’s coverage for VYNDAMAX and VYNDAQEL® (tafamidis meglumine), including out-of-pocket costs
Identify payer requirements for VYNDAMAX and provide information about the prior authorization process as needed†
Identify specialty pharmacy options based on your patient’s insurance coverage. VYNDAMAX is available through multiple specialty pharmacies
Pfizer Field Access Specialists (FAS) can help providers understand the VYNDAMAX access journey
Ask your Pfizer representative to connect you with your local FAS
Pfizer Patient Access Coordinators (PACs) can help your patients during their treatment journey
All patients with a valid VYNDAMAX prescription are eligible to opt in
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2025 Pfizer Inc. All rights reserved.